Day: June 10, 2022

Aspo PlcManagers’ transactionsJune 10, 2022, at 11:00 a.m. Aspo Oyj – Managers’ Transactions ____________________________________________ Person subject to the notification requirement Name: Havsudden Oy Ab Position: Closely associated person (X) Legal person (1): Person Discharging Managerial Responsibilities In Issuer Name: Patricia Allam Position: Member of the Board Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677 Notification type: INITIAL NOTIFICATION Reference number: 15999/6/6 ____________________________________________ Transaction date: 2022-06-07 Venue: OFF-EXCHANGE LIIKETOIMET (XOFF) Instrument type: DEBT INSTRUMENT ISIN: FI4000523170 Nature of the transaction: SUBSCRIPTION Transaction details (1): Volume: 700 000 Unit price: 100 PCT Aggregated transactions (1): Volume: 700 000 Volume weighted average price: 100 PCT Aspo...

Aspo PlcManagers’ transactionsJune 10, 2022, at 11:00 a.m. Aspo Oyj – Managers’ Transactions – Mikko Pasanen ____________________________________________ Person subject to the notification requirement Name: Mikko Pasanen Position: Other senior manager Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677 Notification type: INITIAL NOTIFICATION Reference number: 16024/5/4 ____________________________________________ Transaction date: 2022-06-07 Venue: OFF-EXCHANGE TRANSACTIONS (XOFF) Instrument type: DEBT INSTRUMENT ISIN: FI4000523170 Nature of the transaction: SUBSCRIPTION Transaction details (1): Volume: 100 000 Unit price: 100 PCT Aggregated transactions (1): Volume: 100 000 Volume weighted average price: 100 PCT Aspo Plc Arto MeitsaloCFO For further information, please contact:Arto Meitsalo, CFO, tel. +358 40 551 1422, arto.meitsalo@aspo.com Distribution:Nasdaq...

Aspo PlcManagers’ transactionsJune 10, 2022, at 11:00 a.m. Aspo Oyj – Managers’ Transactions ____________________________________________ Person subject to the notification requirement Name: Procurator-Holding Oy Position: Closely associated person (X) Legal person (1): Person Discharging Managerial Responsibilities In Issuer Name: Salla Pöyry Position: Member of the Board Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677 Notification type: INITIAL NOTIFICATION Reference number: 16030/4/4 ____________________________________________ Transaction date: 2022-06-07 Venue: OFF-EXCHANGE TRANSACTIONS (XOFF) Instrument type: DEBT INSTRUMENT ISIN: FI4000523170 Nature of the transaction: SUBSCRIPTION Transaction details (1): Volume: 1 300 000 Unit price: 100 PCT Aggregated transactions (1): Volume: 1 300 000 Volume weighted average price: 100...

Aspo PlcManagers’ transactionsJune 10, 2022, at 11:00 a.m. Aspo Oyj – Managers’ Transactions – Rolf Jansson ____________________________________________ Person subject to the notification requirement Name: Bo Rolf Jansson Position: Chief Executive Officer Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677 Notification type: INITIAL NOTIFICATION Reference number: 16005/5/4 ____________________________________________ Transaction date: 2022-06-07 Venue: OFF-EXCHANGE TRANSACTIONS (XOFF) Instrument type: DEBT INSTRUMENT ISIN: FI4000523170 Nature of the transaction: SUBSCRIPTION Transaction details (1): Volume: 100 000 Unit price: 100 PCT Aggregated transactions (1): Volume: 100 000 Volume weighted average price: 100 PCT Aspo Plc Arto MeitsaloCFO For further information, please contact:Arto Meitsalo, CFO, tel. +358 40 551 1422, arto.meitsalo@aspo.com Distribution:Nasdaq...

Aspo PlcManagers’ transactionsJune 10, 2022, at 11:00 a.m. Aspo Oyj – Managers’ Transactions – Patricia Allam ____________________________________________ Person subject to the notification requirement Name: Patricia Allam Position: Member of the Board/Deputy member Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677 Notification type: INITIAL NOTIFICATION Reference number: 15997/5/4 ____________________________________________ Transaction date: 2022-06-07 Venue: OFF-EXCHANGE TRANSACTIONS (XOFF) Instrument type: DEBT INSTRUMENT ISIN: FI4000523170 Nature of the transaction: SUBSCRIPTION Transaction details (1): Volume: 200 000 Unit price: 100 PCT Aggregated transactions (1): Volume: 200 000 Volume weighted average price: 100 PCT Aspo Plc Arto MeitsaloCFO For further information, please contact:Arto Meitsalo, CFO, tel. +358 40 551 1422,...

Aspo PlcManagers’ transactionsJune 10, 2022, at 11:00 a.m. Aspo Oyj – Managers’ Transactions – Tatu Vehmas ____________________________________________ Person subject to the notification requirement Name: Tatu Vehmas Position: Member of the Board/Deputy member Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677 Notification type: INITIAL NOTIFICATION Reference number: 16059/7/6 ____________________________________________ Transaction date: 2022-06-07 Venue: OFF-EXCHANGE TRANSACTIONS (XOFF) Instrument type: DEBT INSTRUMENT ISIN: FI4000523170 Nature of the transaction: SUBSCRIPTION Transaction details (1): Volume: 1 500 000 Unit price: 100 PCT Aggregated transactions (1): Volume: 1 500 000 Volume weighted average price: 100 PCT Aspo Plc Arto MeitsaloCFO For further information, please contact:Arto Meitsalo, CFO, tel. +358 40 551 1422,...

WALTHAM, Mass. and STOCKHOLM, Sweden, June 10, 2022 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today reported new analyses of Phase 3 studies that reinforce the robust efficacy and safety profile of EMPAVELI®/Aspaveli® (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH). The data will be presented at the hybrid European Hematology Association (EHA) Congress in Vienna, Austria. New analyses demonstrated that treatment with EMPAVELI resulted in meaningful improvements in quality of life for treatment-naïve patients and suggested the incidence of thrombosis was comparable to eculizumab, a C5 inhibitor. Additionally, a matching-adjusted indirect comparison (MAIC) showed significant improvements in clinical outcomes in treatment-naïve patients who received EMPAVELI compared to C5 inhibitors. “The...

– As of the data cutoff date of 29 April 2022, in addition to improvements in the standard metrics of spleen volume reduction and symptom scores, long term treatment with bomedemstat showed:52% had reductions in mutant allele frequencies, including ASXL1 85% of evaluable patients demonstrated improved or stable fibrosis scores 90% of transfusion independent patients had stable or improved hemoglobin– MF patients initially treated in this Phase 2 study have rolled into an extension study to evaluate longer term safety and impact of bomedemstat on natural history of MF – – Evaluation of bomedemstat in combination with ruxolitinib in patients with MF who have a sub-optimal response to JAK inhibition or are JAK naive to commence – – Company to host virtual investor event on Saturday, 11 June 2022 at...

– The study completed enrollment with 73 patients in April 2022 – – As of the data cutoff of 29 April 2022, bomedemstat demonstrated durability of response with 81% of patients achieving normalized platelet counts for at least 12 weeks – – 58% of patients treated with bomedemstat experienced symptomatic improvement, defined as a decrease in Total Symptom Score, at 24 weeks – – Both JAK2 and CALR mutation burdens were decreased during treatment with bomedemstat – – The EHA data cut represents the last presentation before an End of Phase 2 meeting with FDA expected in 2H22 – – Company to host virtual investor event on Saturday,11 June 2022 at 10:30 AM ET- SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) — Imago BioSciences, Inc. (“Imago” or the “company”)...

Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlight EHA data and provide business updates SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced new data from a large multicenter real-world evidence study supporting the clinical use of Oxbryta® (voxelotor) for the treatment of sickle cell disease (SCD) in patients 12 years of age and older. In addition, Phase 1 data of GBT021601 (GBT601), the company’s next-generation sickle hemoglobin (HbS) polymerization inhibitor, support its progression into the Phase 2 portion of a Phase 2/3 trial that is anticipated to commence by...